Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 7 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

4(50.0%)

Phase 2

4(50.0%)

8Total

Phase 1(4)

Phase 2(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT06628362Phase 2Active Not Recruiting

A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

Role: lead

NCT06525935Phase 2Completed

A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

Role: lead

NCT05110846Phase 2Completed

A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus

Role: lead

NCT05814107Phase 1Completed

Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes Mellitus

Role: collaborator

NCT04838405Phase 1Completed

A Study of CT-388 in Otherwise Healthy Overweight and Obese Adults and Patients With Type 2 Diabetes Mellitus

Role: lead

NCT06062069Phase 2Completed

A Study of CT-868 in Type 1 Diabetes Mellitus

Role: lead

NCT04973111Phase 1Completed

A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose

Role: lead

NCT05794581Phase 1Completed

A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes

Role: lead

All 8 trials loaded